Cefadroxil
As of the edition of 20 October 2026, Cefadroxil is a small molecule: marketed, first approved in 1981 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Duracef
- First approved
- 1 June 1981 (ES)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Jamp Pharma; 2 holders in all
- Registered trials
- 8, 0 stopped early
- Disease areas
- Infections; Bones, joints and muscles; Hormones; Lungs and airways; Nervous system; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Jamp Pharma | Applicant | 2024 to now |